Studies on the mechanism of antifungal action of aculeacin A. 1982

H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto

Aculeacin A was lethal for proliferating cultures of C. albicans. However, there was a paradoxical relationship between the drug concentration and the fungicidal activity; the lethal effect was greatest at levels of 0.08 to 1.25 microgram/ml and increases in the drug concentration above this range reduced its lethal effect. A similar anomalous dose-response patterns were also observed for the inhibitory effect of the drug on several cellular and subcellular biochemical activities. Association of this lethal effect of the drug was the formation of visible cell aggregates and the development of extremely huge forms in treated cultures. Aculeacin A induced osmotically fragile cells and viability of treated cultures was markedly reversed under high osmolarity. Tracer experiments and chemical analysis revealed that synthesis of alkali insoluble glucan was inhibited by the drug to a greater extent than synthesis of mannan and any other species of macromolecules, with resultant formation of alkali-insoluble glucan-deficient cells. Aculeacin A inhibited synthesis of beta-glucan from UDP-glucose catalyzed by cell-free extracts from C. albicans and S. cerevisiae. These data are consistent with the view that one of the principal target of aculeacin A action is on the beta-1,3-glucan synthetase reaction.

UI MeSH Term Description Entries
D010456 Peptides, Cyclic Peptides whose amino acid residues are linked together forming a circular chain. Some of them are ANTI-INFECTIVE AGENTS; some are biosynthesized non-ribosomally (PEPTIDE BIOSYNTHESIS, NON-RIBOSOMAL). Circular Peptide,Cyclic Peptide,Cyclic Peptides,Cyclopeptide,Orbitide,Circular Peptides,Cyclopeptides,Orbitides,Peptide, Circular,Peptide, Cyclic,Peptides, Circular
D002176 Candida albicans A unicellular budding fungus which is the principal pathogenic species causing CANDIDIASIS (moniliasis). Candida albicans var. stellatoidea,Candida stellatoidea,Dematium albicans,Monilia albicans,Myceloblastanon albicans,Mycotorula albicans,Parasaccharomyces albicans,Procandida albicans,Procandida stellatoidea,Saccharomyces albicans,Syringospora albicans
D005936 Glucans Polysaccharides composed of repeating glucose units. They can consist of branched or unbranched chains in any linkages. Glucan,Polyglucose,Polyglucoses,Glucan (BO),Glucose Polymer,Polycose,Polymer, Glucose
D000935 Antifungal Agents Substances that destroy fungi by suppressing their ability to grow or reproduce. They differ from FUNGICIDES, INDUSTRIAL because they defend against fungi present in human or animal tissues. Anti-Fungal Agents,Antifungal Agent,Fungicides, Therapeutic,Antibiotics, Antifungal,Therapeutic Fungicides,Agent, Antifungal,Anti Fungal Agents,Antifungal Antibiotics

Related Publications

H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto
January 1975, Nihon saikingaku zasshi. Japanese journal of bacteriology,
H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto
April 1977, The Journal of antibiotics,
H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto
September 1983, The Biochemical journal,
H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto
April 1977, The Journal of antibiotics,
H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto
August 2004, European journal of biochemistry,
H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto
June 1969, Antibiotiki,
H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto
February 1967, Antibiotiki,
H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto
October 2001, Medical mycology,
H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto
February 1966, Therapie der Gegenwart,
H Yamaguchi, and T Hiratani, and K Iwata, and Y Yamamoto
January 1969, Dermatologia internationalis,
Copied contents to your clipboard!